Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.

Caccese M, Indraccolo S, Zagonel V, Lombardi G.

Crit Rev Oncol Hematol. 2019 Mar;135:128-134. doi: 10.1016/j.critrevonc.2018.12.002. Epub 2019 Feb 1. Review.

PMID:
30819441
2.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

3.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
4.

Biomarkers of response to PD-1/PD-L1 inhibition.

Maleki Vareki S, Garrigós C, Duran I.

Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9. Review.

5.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Review. French.

PMID:
30337201
6.

[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].

Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S.

Bull Cancer. 2018 Jul - Aug;105(7-8):686-695. doi: 10.1016/j.bulcan.2018.04.011. Epub 2018 Jun 20. Review. French.

PMID:
29933886
7.

Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.

Sinnadurai M, McDonald KL.

J Neurooncol. 2017 May;132(3):359-372. doi: 10.1007/s11060-017-2390-3. Epub 2017 Mar 14. Review.

PMID:
28293764
8.

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Park JA, Cheung NV.

Cancer Treat Rev. 2017 Jul;58:22-33. doi: 10.1016/j.ctrv.2017.05.006. Epub 2017 Jun 1. Review. Erratum in: Cancer Treat Rev. 2017 Nov;60:158.

9.

PD-1/PD-L1 and immunotherapy for pancreatic cancer.

Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y.

Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18. Review.

PMID:
28826722
10.

Immune checkpoint blockade therapy for bladder cancer treatment.

Kim J.

Investig Clin Urol. 2016 Jun;57 Suppl 1:S98-S105. doi: 10.4111/icu.2016.57.S1.S98. Epub 2016 May 26. Review.

11.

Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Miyazaki T, Ishikawa E, Matsuda M, Akutsu H, Osuka S, Sakamoto N, Takano S, Yamamoto T, Tsuboi K, Matsumura A.

J Neurooncol. 2017 Jun;133(2):277-285. doi: 10.1007/s11060-017-2451-7. Epub 2017 Apr 26.

PMID:
28447277
12.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
13.

[Current events in immunotherapy for upper aerodigestive tract cancer].

Outh-Gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C.

Ann Pathol. 2017 Feb;37(1):79-89. doi: 10.1016/j.annpat.2016.12.013. Epub 2017 Jan 19. Review. French.

PMID:
28111039
14.

A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.

Kattan J, Rassy EE, Assi T, Bakouny Z, Pavlidis N.

Crit Rev Oncol Hematol. 2018 Oct;130:60-69. doi: 10.1016/j.critrevonc.2018.08.001. Epub 2018 Aug 7. Review.

PMID:
30196913
15.

[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].

Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, Damotte D, Lantuejoul S.

Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3. Review. French.

PMID:
28162296
16.

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].

Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F.

Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26. Review. French.

PMID:
28131419
17.

Role of immune-checkpoint inhibitors in lung cancer.

Jain P, Jain C, Velcheti V.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075. Review.

18.

A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.

Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X.

Urol Oncol. 2017 Jan;35(1):14-20. doi: 10.1016/j.urolonc.2016.10.004. Epub 2016 Nov 3. Review.

PMID:
27816403
19.

Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

Nowicki TS, Hu-Lieskovan S, Ribas A.

Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303. Review.

20.

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.

Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.

Supplemental Content

Support Center